19 February 2021 - Late treatment study
N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia
et al., Pulmonologiya, doi:10.18093/0869-0189-2021-31-1-21-29 (Peer Reviewed)
RCT 46 hospitalized patients with moderate COVID-19 pneumonia, 24 treated wth N-acetylcysteine, showing significantly shorter hospitalization with treatment. NAC 1,200 – 1,500mg/day intravenously.
|
hospitalization time, 15.4% lower, relative time 0.85, p < 0.001, treatment 24, control 22.
|
|
relative improvement in lung Ct, 50.7% better, RR 0.49, p < 0.001, treatment 24, control 22.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Gaynitdinova et al., 2/19/2021, Randomized Controlled Trial, Russia, Europe, peer-reviewed, 6 authors, average treatment delay 7.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.